Aurobindo Pharma Board Meeting on Aug 5 to Approve Q1 FY27 Results

Aurobindo Pharma Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda for this meeting is to consider and approve the standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026. The company also confirmed that the trading window, which was initially set to close until 48 hours after the results declaration, will now remain closed until August 7, 2026, and will reopen on August 8, 2026. This announcement follows SEBI regulations regarding board meetings and disclosure requirements.